贵州百灵制药有限公司电商营销策略研究

Research on E-Commerce Marketing Strategy of Guizhou Bailing Pharmaceutical Co., Ltd.

摘要: 在“互联网 + 医药健康”政策红利释放与消费需求迭代升级的双重驱动下，医药电商已成为药企突破增长瓶颈的核心赛道。贵州百灵作为以苗药为核心优势的上市民族药企，坐拥9个年销售额过亿的黄金单品，年度整体销售额超40亿元，但受传统渠道竞争加剧影响，2025年营业收入同比下滑24.28%，电商业务被寄予数字化转型与品类护城河构建的厚望。本文基于4P营销理论、整合营销传播(IMC)理论及数据驱动营销理论，构建“基础架构–协同机制–赋能工具”三维整合分析框架，从产品、价格、渠道、推广四大维度剖析贵州百灵电商营销现状，诊断出产品协同不足、渠道覆盖不均、数据驱动薄弱、品牌年轻化欠缺及组织支撑乏力等问题，最终提出“产品协同化、渠道全域化、数据精准化、品牌年轻化、组织专业化”的优化路径，既为贵州百灵提升电商业务贡献率提供实操指导，也为同类民族药企全渠道转型提供参考。

Abstract: Driven by the release of “Internet + Healthcare” policy dividends and the iteration and upgrading of consumer demand, pharmaceutical e-commerce has become a core track for pharmaceutical enterprises to break the growth bottleneck. As a listed ethnic pharmaceutical company with core advantages in Miao medicine, Guizhou Bailing has 9 golden single products with annual sales exceeding 100 million yuan and an overall annual sales volume of over 4 billion yuan. However, affected by the intensification of competition in traditional channels, its operating income decreased by 24.28% year-on-year in 2025, and the e-commerce business is expected to realize digital transformation and build a category moat. Based on the 4P marketing theory, Integrated Marketing Communication (IMC) theory and data-driven marketing theory, this paper constructs a three-dimensional integrated analysis framework of “basic structure-coordination mechanism-enabling tool”, analyzes the current situation of Guizhou Bailing’s e-commerce marketing from four dimensions of product, price, channel and promotion, identifies problems such as insufficient product synergy, uneven channel coverage, weak data drive, lack of brand youthfulness and insufficient organizational support, and finally puts forward the optimization path of “product synergy, channel omnipotence, data precision, brand youthfulness and organizational specialization”. It not only provides practical guidance for Guizhou Bailing to improve the contribution rate of e-commerce business, but also offers reference for the omni-channel transformation of similar ethnic pharmaceutical enterprises.